News & Views
Expert to Strengthen eCOA Offering
Oct 12 2019 Read 733 Times
Clinical trials solutions provider Kayentis has appointed Estelle Haenel, PharmD,PhD as Medical Director, a role that includes facilitating both sites’ and patients’ adoption of eCOA (electronic Clinical Outcome Assessment) solutions as these technologies have matured.
With more than 25 years’ pharma industry experience, including 18 years in clinical science and operations, she will bring to the forefront of the company strategy the perspectives of patients, sites and customers. Improving overall patient engagement in clinical trials, will help pharmas, biotechs and CROs better meet the increasing regulatory requirements for more data and more patient-centric studies. The company’s new generation eCOA platform, Clin’form3, is designed to improve patient engagement, connection with medical devices and wearables, as well as BYOD implementation.
“Kayentis is delighted to welcome Estelle,” said Guillaume Juge, company CEO. “She brings extensive pharma industry experience and high-level skills that will consolidate our clinical knowledge, enhance our focus and reinforce the quality of care we provide to sites and patients. She will make a significant contribution to helping our customers across Europe, North America and Asia
design and implement robust digital trial data collection studies.
Concentrated on phases IIB/III the business is increasingly extending its services towards late phase studies and Real-World Evidence (RWE). It has conducted digital data collection for over 200 clinical trials in 75 countries (9,000 sites and 70,000 patients) employing 90 different languages in a broad range of therapeutic areas.
“Kayentis’ growth has been impressive. This is due to the quality, energy and dedication of its teams,” said Estelle Haenel. “In its positioning as 100% eCOA-focused, it has specially trained staff fully dedicated to preparing, delivering and maintaining eCOA solutions for customers. I have confidence in Kayentis’ high-quality and innovative eCOA solutions to support efficient clinical trials.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...
View all digital editions
Sep 21 2020 Budapest, Hungary
Sep 22 2020 Moscow, Russia
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria
Oct 06 2020 Digital Forum